Combining oncology drug development and biomarker technology experience to improve cancer care
Vice President, Clinical Development
Vicki Kelemen has served as Vice President of Clinical Development and Investor Relations since 2018, and previously as Vice President of Corporate Communications from 2017 to 2018 and Senior Director of Marketing Communications from 2015 to 2017.
Prior to joining Trovagene, Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive marketing and communications management positions and lead the launch of several novel products with pharmabiotech companies focused in therapeutics, diagnostics and medical devices, including Amylin, Maxim, Agouron (Pfizer) and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.
Ms. Kelemen has a BS degree from the University of California at Davis.